Waldenstrom Macroglobulinemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
L
Recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Scottsdale, Arizona
  • +55 more
2022-01-12
Jan 12, 2022
S
Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • Boston, Massachusetts
  • +1 more
2021-12-29
Dec 29, 2021
T
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Washington, District of Columbia
  • +3 more
2022-01-12
Jan 12, 2022
N
Recruiting
  • Waldenstrom Macroglobulinemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-01-05
    Jan 5, 2022
    H
    Not yet recruiting
    • CLL/SLL
    • +8 more
    • (no location specified)
    2021-12-14
    Dec 14, 2021
    J
    Enrolling by invitation
    • Chronic Lymphocytic Leukemia
    • +6 more
    • Duarte, California
    • +165 more
    2021-12-30
    Dec 30, 2021
    L
    Available
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • +4 more
    • (no location specified)
    2021-12-15
    Dec 15, 2021
    W
    Recruiting
    • Waldenstrom Macroglobulinemia
    • +6 more
    • New York, New York
      Weill Cornell Medicine
    2021-12-21
    Dec 21, 2021
    F
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • MRD and clonal evolution
    • Milano, MI, Italy
    • +13 more
    2021-12-17
    Dec 17, 2021
    A
    Withdrawn
    • Asymptomatic COVID-19 Infection Laboratory-Confirmed
    • +8 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    2021-12-01
    Dec 1, 2021
    C
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Ibrutinib / Bortezomib / Rituximab
    • Berlin, Germany
    • +14 more
    2021-12-06
    Dec 6, 2021
    J
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Chiba, Japan
    • +8 more
    2021-12-02
    Dec 2, 2021
    J
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Changchun, China
    • +5 more
    2021-12-02
    Dec 2, 2021
    B
    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +7 more
    • BR101801 (Phase Ia)
    • +2 more
    • Seoul, Korea, Republic of
    • +2 more
    2021-11-19
    Nov 19, 2021
    C
    Recruiting
    • Waldenstrom Macroglobulinemia
    • +8 more
    • CLR 131 single dose
    • +2 more
    • Redlands, California
    • +14 more
    2021-11-30
    Nov 30, 2021
    J
    Recruiting
    • IgM MGUS
    • +2 more
    • Boston, Massachusetts
    • +1 more
    2021-11-22
    Nov 22, 2021
    E
    Recruiting
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • +6 more
    • Miami, Florida
    • +2 more
    2021-11-19
    Nov 19, 2021
    N
    Recruiting
    • Lymphoma, Non-Hodgkin
    • +9 more
    • NKX019
    • Denver, Colorado
    • +4 more
    2021-11-16
    Nov 16, 2021
    R
    Recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +36 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    2021-11-16
    Nov 16, 2021
    A
    Terminated
    • Multiple Myeloma
    • Waldenstrom Macroglobulinemia
    • Scottsdale, Arizona
    • +18 more
    2021-11-15
    Nov 15, 2021
    J
    Recruiting
    • Waldenstrom Macroglobulinemia
    • DASATINIB
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    2021-11-15
    Nov 15, 2021
    D
    Recruiting
    • Waldenstrom Macroglobulinemia
    • MYD88 Gene Mutation
    • Boston, Massachusetts
    • +1 more
    2021-11-15
    Nov 15, 2021
    C
    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    2021-11-02
    Nov 2, 2021
    V
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +11 more
    • Zilovertamab vedotin
    • Duarte, California
    • +11 more
    2021-11-02
    Nov 2, 2021